Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$3.90 USD
+0.28 (7.73%)
Updated May 24, 2024 03:58 PM ET
After-Market: $3.94 +0.04 (1.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
Windtree Therapeutics, Inc. [WINT]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Istaroxime Poised to Navigate Late-Stage Development; Initiate at Neutral With a $1 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive New Preclinical Data With Istaroxime and Pipeline Candidate CVie-216; Reiterate Neutral and $1.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: H.C. Wainwright & Co., Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
RDS Epidemiology and Pending Phase 2a Data in 3Q
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Good Things Come in Tiny Particles; Initiating with a Buy Rating and a $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|